Stockwinners Market Radar for May 15, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:05 EDT Cathie Wood's ARK Investment buys 50K shares of Roblox today

19:52 EDT Public Storage director buys $599.5K in common stock - In a regulatory filing, Public Storage disclosed that its director Kristy Pipes bought 2.1K shares of common stock on May 14th in a total transaction of $599.5K.

19:50 EDT Earlyworks Co Ltd - ADR trading halted, news pending

18:21 EDT AES Corp. to sell its equity Interest in AES Brasil for about $640M - The AES Corporation "announced that it has agreed to sell its 47.3% equity interest in AES Brasil to Auren Energia for approximately $640 million in proceeds to AES. This sale will be completed in conjunction with a merger between AES Brasil and Auren Energia, with AES Brasil shares valued at approximately 11.55 Brazilian Real per share, before purchase price adjustments. Including this sale, as well as others closed in 2023 and 2024, AES will have achieved more than half of its $3.5 billion asset sale proceeds target through 2027."

18:04 EDT Elliott buys Transocean, sells Valaris in Q1 - Paul Singer's Elliott Management disclosed in an SEC filing its holdings as of March 31, 2024. The fund's new buys during the first quarter included, in order of size, Transocean (RIG), HDFC Bank (HDB), iShares Bitcoin Trust (IBIT), and Nvidia (NVDA). Elliott exited a number of positions during the quarter, including by size of previous position iShares iBoxx $ Investment Grade Corporate Bond ETF (LQD), Fidelity National (FNF), Valaris (VAL), and Reservoir Media (RSVR). The fund increased its stake in Suncor Energy (SU), Match Group (MTCH), BioMarin (BMRN), Etsy (ETSY), and Liberty Broadband Class C (LBRDK), while it reduced its stake in Peabody Energy (BTU), Marathon Petroleum (MPC), Howmet (HWM), and Seadrill (SDRL). Elliott's top holdings as of March 31, in order of size, were Suncor Energy, Triple Flag (TFPM), Marathon, Pinterest (PINS), and NRG Energy (NRG).

17:55 EDT Soros buys Okta, cuts Amazon in Q1 - George Soros' Soros Fund Management disclosed in an SEC filing its holdings as of March 31, 2024. The fund's new buys during the first quarter included, by size of position, Cerevel Therapeutics (CERE), Okta (OKTA), WestRock (WRK), PG&E (PCG), and Sunrun (RUN). Soros exited five holdings during the quarter, including by size of previous position iShares Russell 2000 ETF (IWM), SPDR S&P 500 ETF Trust (SPY), SPDR Euro Stoxx 50 ETF (FEZ), Las Vegas Sands (LVS), and Birkenstock (BIRK). The fund increased its stake in multiple holdings, including by size of previous position Alphabet Class A (GOOGL), Aramark (ARMK), D.R. Horton (DHI), American Equity (AEL), and SPDR S&P Regional Banking ETF (KRE). Soros reduced its stake in multiple holdings, including by size of previous position Novo (NVO), Sempra (SRE), CRH (CRH), Amazon (AMZN), and AerCap (AER). The fund's top holdings as of March 31, in order of size, were Alphabet Class A, AerCap, American Equity, Novo, and Cerevel.

17:39 EDT Verve Therapeutics COO buys $475.8K in common stock - In a regulatory filing, Verve Therapeutics disclosed that its COO/General Counsel Andrew Ashe bought 76K shares of common stock on May 14th in a total transaction of $475.8K. Shares of Verve Therapeutics are up 4.3% afterhours at $6.50.

17:33 EDT TSR to be acquired by Vienna Parent Corporation for $13.40 per share - Vienna Parent Corporation, a newly formed special purpose entityformed by Justin Christian, announced that it has entered into a definitive agreement to acquire TSR, Inc. Under the terms of the agreement, Vienna Acquisition Corporation, an affiliate and wholly-owned subsidiary of Vienna Parent, will commence a tender offer to purchase all of the outstanding shares of TSR for $13.40 per share, representing an equity value of approximately $29 million. The total consideration payable to TSR's shareholders represents a 73.8% premium to TSR's closing price on May 14, 2024. The transaction has been approved by the boards of directors of both companies. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions, including the tender of a majority of the outstanding shares of TSR's common stock.

17:31 EDT Everest Group raises quarterly dividend to $2.00 per share from $1.75 - This dividend will be payable on or before June 14, 2024 to all shareholders of record as of May 29, 2024.

17:16 EDT Third Point takes new position in Alphabet, exits U.S. Steel - Third Point LLC disclosed in an SEC filing its holdings as of March 31. Third Point's new buys during the quarter included, by size of position, Alphabet (GOOGL), Advance Auto (AAP), Marvell Technology (MRVL), and Goldman Sachs (GS). Third Point exited four positions during the quarter, including by size of previous position, U.S. Steel (X), DuPont de Nemours (DD), McKesson (MCK), and BioMarin (BMRN). Third Point increased its stake in a number of holdings, including by size of previous position, Amazon (AMZN), Meta Platforms (META), Intercontinental Exchange (ICE), Apollo Global (APO), and Corpay (CPAY). Third Point reduced its stake in a number of holdings, including by size of previous position, International Flavors (IFF), Uber (UBER), Microsoft (MSFT), Bath & Body Works (BBWI), and Vistra Corp (VST). Third Point's top holdings as of March 31, in order of size, were PG&E (PCG), Amazon, Microsoft, Bath & Body Works, and Meta Platforms.

17:01 EDT Icahn takes stakes in CVR Partners and JetBlue, exits position in FirstEnergy - Carl Icahn's Icahn Capital disclosed in an SEC filing its holdings as of March 31. Icahn's two new buys during the quarter included, by size of position, CVR Partners (UAN) and JetBlue (JBLU). Icahn exited two positions during the quarter, including by size of previous position, FirstEnergy (FE) and Newell Brands (NWL). Icahn increased its stake in one holding, International Flavors (IFF). Icahn's top holdings as of March 31, in order of size, were Icahn Enterprises (IEP), CVR Energy (CVI), Southwest Gas (SWX), Bausch Health (BHC) and International Flavors.

16:53 EDT Lone Pine Capital takes new position in Intuit, exits Alphabet stake - Stephen Mandel's Lone Pine Capital disclosed in an SEC filing its holdings as of March 31. Lone Pine's four new buys during the quarter included, by size of position, Intuit (INTU), Blackstone (BX), Philip Morris (PM), and GE (GE). Lone Pine exited a number of positions during the quarter, including by size of previous position, Alphabet (GOOGL), TransDigm (TDG), BILL Holdings (BILL), Tempur Sealy (TPX), and Floor & Decor (FND). Lone Pine increased its stake in a number of holdings, including by size of previous position, Block (SQ), Meta Platforms (META), Bath & Body Works (BBWI), Dick's Sporting Goods (DKS), and ASML (ASML). Lone Pine reduced its stake in a number of holdings, including by size of previous position, Mastercard (MA), Workday (WDAY), EPAM Systems (EPAM), Live Nation (LYV), and TSMC (TSM). Lone Pine's top holdings as of March 31, in order of size, were Meta Platforms, Amazon (AMZN), TSMC, Microsoft (MSFT), and Salesforce.

16:46 EDT Galapagos and BCA collaborating for U.S.-based CAR-T manufacturing network - Galapagos and Blood Centers of America, BCA, announced that they have entered into a strategic collaboration for the decentralized manufacturing of Galapagos' CAR-T cell therapies through BCA's network in the U.S. Under the terms of the collaboration agreement, BCA will provide access to its extensive network of over 50 community blood centers in 43 states for Good Manufacturing Practice compliant manufacturing for Galapagos' CAR-T hemato-oncology clinical program. .."Our collaboration with Blood Centers of America marks a major milestone for Galapagos' U.S. expansion by establishing centers for support of our pivotal studies, with the potential to be used for commercial introduction. Working with BCA's extensive nationwide network allows us to efficiently scale up decentralized CAR-T therapy manufacturing across the U.S., while their established infrastructure helps us harmonize operations and access apheresis capacity," said Dr. Paul Stoffels1, CEO and Chairman of the Board of Directors of Galapagos. "This agreement complements the existing collaborations between Galapagos and Landmark Bio and Thermo Fisher Scientific and translates to a significant step forward in our aspiration to bring CAR-T therapies to more patients with a vein-to-vein time of just seven days."

16:40 EDT Four Corners Property Trust acquires Longhorn Steakhouse property for $2.0M - Four Corners Property Trust is pleased to announce the acquisition of a Longhorn Steakhouse property for $2.0 million. The property is located in a highly trafficked corridor in Illinois and is corporate-operated under a net lease. The transaction was priced at a cap rate in range with previous FCPT transactions.

16:35 EDT Palo Alto Networks, IBM to jointly provide AI-powered security offerings - Palo Alto Networks (PANW) and IBM (IBM)announced a broad-reaching partnership to deliver AI-powered security outcomes for customers. The announcement is a testament to Palo Alto Networks' and IBM's commitment to each other's platforms and innovative capabilities. The expanding and complex enterprise technology landscape, driven by digital transformation and the rapid growth of AI, presents significant cybersecurity challenges. To address increasingly sophisticated threats and evolving attack surfaces, organizations are prioritizing comprehensive security platforms that are underpinned by AI. Palo Alto Networks and IBM aim to help streamline and transform security operations, stop threats at scale, and accelerate incident remediation for their customers with the complete AI-powered approach that is required. These industry dynamics, paired with today's partnership announcement, present significant opportunities for both companies. As part of this expanded partnership, Palo Alto Networks has agreed to acquire IBM's QRadar SaaS assets, including QRadar intellectual property rights, subject to customary closing conditions. Upon closing, Palo Alto Networks and IBM will facilitate the migration of QRadar SaaS clients to Cortex XSIAM, the leading next-generation security operations platform, with advanced AI-powered threat protection supported by 3,000 out-of-the-box detectors. On-premise QRadar clients who wish to remain on QRadar on-prem will continue to receive IBM features and support including security, usability and critical bug fixes, as well as updates to existing connectors and the ability to expand consumption. For both QRadar SaaS and on-prem clients who chose to migrate to Cortex XSIAM, the companies, along with their ecosystem of business partners, will closely collaborate to enable a smooth transfer, with IBM and Palo Alto Networks offering no-cost migration services to qualified customers. As part of this agreement, IBM will receive incremental payments from Palo Alto Networks for QRadar on-prem clients who choose to migrate to the Cortex XSIAM platform.

16:32 EDT Travel + Leisure boosts share repurchase authorization by $500M - The board of directors of Travel + Leisure Co. declared a regular cash dividend on the company's common stock of 50c per share, payable June 28, 2024 to shareholders of record as of June 14, 2024. The Board of Directors also approved an increase to the authorized capacity of the Company's share repurchase program by $0.5B.

16:27 EDT Berkshire Hathaway takes new position in Chubb, exits HP Inc stake - Warren Buffett's Berkshire Hathaway disclosed in an SEC filing its holdings as of March 31. Berkshire's one new buy during the quarter was Chubb (CB). Berkshire exited one position during the quarter, HP Inc (HPQ). Berkshire increased its stake in one holding, Occidental (OXY). Berkshire reduced its stake in a number of holdings, including by size of previous position, Apple (AAPL), Paramount (PARA), Sirius XM (SIRI), Louisiana- Pacific (LPX), and Chevron (CVX). Berkshire's top holdings as of March 31, in order of size, were Apple, Bank of America (BAC), American Express (AXP), Coca-Cola (KO), and Chevron.

16:25 EDT Chubb jumps 6% to $269.18 after Berkshire reports stake

16:19 EDT Diamond Offshore awarded two-year contract extension for drillship - Diamond Offshore has executed a two-year contract extension with Anadarko Petroleum Corporation, a wholly-owned subsidiary of Occidental, in the U.S. Gulf of Mexico for the Ocean BlackHawk, commencing in November 2024 in direct continuation of the rig's current contract. This contract extension represents approximately $350M dollars of additional backlog, excluding any managed pressure drilling services, and replaces the one-year priced option that was agreed in May 2023. Anadarko retains three one-year unpriced options. Total contract backlog is now approximately $2.1B.

16:18 EDT Appaloosa takes new positions in Adobe and Boeing, boosts Alibaba stake - David Tepper's Appaloosa Management disclosed in an SEC filing its holdings as of March 31. Appaloosa's new buys during the quarter included, by size of position, Adobe (ADBE), JD.com (JD), and Boeing (BA). Appaloosa exited a number of positions during the quarter, including by size of previous position, HCA Healthcare (HCA), FMC Corp (FMC), Whirlpool (WHR), Mohawk Industries (MHK), and General Motors (GM). Appaloosa increased its stake in a number of holdings, including by size of previous position, Alibaba (BABA), Oracle (ORCL), PDD (PDD), Baidu (BIDU), and UPS (UPS). Appaloosa reduced its stake in holdings, including by size of previous position, Uber (UBER), Meta Platforms (META), Intel (INTC), Macy's (M), and Microsoft (MSFT). Appaloosa's top holdings as of March 31, in order of size, were Alibaba, Amazon (AMZN), Microsoft, Meta Platforms, and Nvidia (NVDA).

16:17 EDT U.S. Silica increasing prices in Industrial and Specialty Products segment - U.S. Silica's Industrial and Specialty Products segment will increase prices for most of its non-contracted silica, aplite, diatomaceous earth, clay, perlite, and cellulose products used primarily in glass, filtration, foundry, paints, coatings, elastomers, roofing, chemicals, recreation, building products, renewable diesel, industrial oil, and other applications. Price increases will range up to 20% depending on the product and grade and go into effect for shipments beginning July 1.

16:14 EDT Cisco reports Q3 adjusted gross margin 68.3%, GAAP gross margin 65.1%

16:13 EDT QuidelOrtho opens new distribution center in Pedricktown, NJ - QuidelOrtho Corporation has launched a second state-of-the-art United States distribution center in Pedricktown, New Jersey. "At QuidelOrtho, we embrace a culture of relentless improvement. With the startup of our second distribution center in the United States, we're making great strides in maintaining and enhancing a truly robust supply chain approach to distribute our products," said Phil McLellan, Senior Vice President, Operations, QuidelOrtho. "This milestone underscores our dedication to operational excellence and responsiveness to customer feedback."

16:12 EDT Robinhood reports April assets under custody $123.3B - Robinhood reported select monthly operating data for April. Funded Customers at the end of April were 24M, up approximately 90 thousand from March. Assets under custody at the end of April were $123.3B, down 5% from March. Net deposits were $4.9B in April, translating to a 45% annualized growth rate relative to March AUC. Over the last twelve months, net deposits were $27.4B, translating to an annual growth rate of 35% relative to April 2023 AUC. Trading volumes in April were higher for options and lower for equities and crypto relative to March. Equity notional trading volumes were $70.7B. Options contracts traded were 126.6M. Crypto notional trading volumes were $10.1B. Margin balances at the end of April were $4.1B, unchanged from the end of March. Total cash sweep balances at the end of April were $19.1B, up $0.1B or 1% from the end of March. Total securities lending revenue in April was $21M, up 24% from March.

16:10 EDT Bunge raises quarterly dividend to 68c per share from 66c - The dividend will be paid June 3rd to shareholders of record on May 20th.

16:09 EDT Mobile Infrastructure names Paul Gohr CFO - Mobile Infrastructure Corporation announced the appointment of Paul Gohr as Chief Financial Officer, effective May 16, 2024. Gohr takes on the CFO responsibility from Stephanie Hogue, who will remain in her role as President and a member of the Board of Directors. "We are pleased to welcome Paul to the BEEP team. He is a results-driven and accomplished executive with an impressive track record of accounting excellence and change management," said Manuel Chavez, CEO and Co-Chairman of the Board of Directors. "Paul's public company experience will benefit all stakeholders, and he adds bench strength and expertise to our team as we continue to build the Company's financial performance."

16:08 EDT Kodiak Sciences reports Q1 EPS (82c), consensus ($1.07) - Kodiak ended Q1 with $245.9M of cash and cash equivalents and believes current cash will support current and planned operations into 2026. "We continue to make excellent operational progress with our three clinical programs of tarcocimab, KSI-501 and KSI-101, as well as on our duet and triplet research programs," said CEO Victor Perlroth. "We are enrolling well in GLOW2 and remain on track to activate mid-year our next Phase 3 study DAYBREAK in wet AMD which is designed to investigate the efficacy, durability and safety of tarcocimab and KSI-501 in parallel against aflibercept. We also expect to initiate Phase 1b enrollment in June for the APEX study of KSI-101, our anti-IL-6, VEGF-trap bispecific protein, in patients with macular edema associated with inflammation. We were pleased to share the advancement on our growing repertoire of novel small molecules and biologics for the duet and triplet platforms at the ARVO 2024 Annual Meeting recently. The duets and triplets are designed as a modular platform that embeds diverse active pharmaceutical ingredients including small molecules, proteins, peptides, macrocycles, and oligonucleotides in the biopolymer backbone to enable high drug antibody ratio medicines with targeted, multi-specific, tailored modulation of biological pathways for ophthalmic and systemic diseases."

16:01 EDT OFS Credit estimates NAV per share of $7.29-$7.39 as of April 30, 2024 - OFS Credit Company announced the following net asset value estimate as of April 30, 2024. Management's unaudited estimate of the range of our NAV per share of our common stock as of April 30, 2024 is between $7.29 and $7.39. This estimate is not a comprehensive statement of our financial condition or results for the month ended April 30, 2024. This estimate did not undergo the Company's typical quarter-end financial closing procedures. We advise you that the final determination of our NAV per share as of April 30, 2024, which will be reported in our Semi-Annual Report on Form N-CSRS, may differ from this estimate.

15:25 EDT Netflix says ad tier now has 40M global monthly active users - Netflix said that its ad-supported tier now has 40M global monthly active users, up from 5M a year prior. Over 40% of all signups in the ads countries now come from the ads plan, the company said. Additionally, Netflix said it will launch an in-house advertising technology platform, by the end of 2025. This will give advertisers new ways to buy, new insights to leverage, and new ways to measure impact. This summer, Netflix will also expand its buying capabilities to include The Trade Desk, Google's Display & Video 360, and Magnite who will join Microsoft as the main programmatic partners for advertisers. The company said it currently has 270M total subscribers. Reference Link

14:02 EDT Baxter says Vantive separation expected in second half of 2024 - Baxter International announced the mission and logo for its proposed kidney care and acute therapies company, to be named Vantive. Baxter announced in 2023 plans to create a new Kidney Care company from its Renal Care and Acute Therapies businesses. The new Vantive branding will come into effect when the separation occurs, which is currently expected in the second half of 2024, via either a sale to a private equity investor or a spinoff into a publicly traded company. Until completion of the proposed separation, the Kidney Care business will continue to operate as Baxter. "With the reveal of our mission and logo, we have reached another critical milestone in our journey to establish Vantive. From our legacy as a pioneer in kidney care to our position as a market leader in chronic and acute therapies, we maintain a unique vantage point to help fulfill the pivotal needs of today's clinicians and patients," said Chris Toth, executive vice president and group president, Kidney Care at Baxter, who is to serve as Chief Executive Officer of Vantive upon separation.

13:50 EDT Genius Group LTD trading resumes

13:10 EDT Genius Group LTD trading halted, news pending

12:51 EDT U.S. initiates investigations of solar imports from four Asian nations - The U.S. Department of Commerce announced the initiation of antidumping and countervailing duty investigations of crystalline silicon photovoltaic cells, whether or not assembled into modules, from Cambodia, Malaysia, Thailand, and the Socialist Republic of Vietnam. Publicly traded companies in the solar energy space include Array Technologies (ARRY), Canadian Solar (CSIQ), Emeren (SOL), FTC Solar (FTCI), First Solar (FSLR), JinkoSolar (JKS), Maxeon Solar (MAXN), Shoals Technologies (SHLS), SolarEdge (SEDG) and SunPower (SPWR).Reference Link

12:36 EDT Ubisoft's 'Assassin's Creed Shadows' out November 15 - Ubisoft (UBSFY) announced that its upcoming game "Assassin's Creed Shadows" will release on November 15, 2024. The game will be available on PC, PlayStation 5 (SONY), Xbox (MSFT), and Amazon Luna (AMZN). Reference Link

12:05 EDT Blue Star Foods announces 1-for-50 reverse stock split - Blue Star Foods will effect a 1-for-50 reverse stock split of its authorized and issued and outstanding shares of Class A common stock, par value $0.0001 per share. The Reverse Stock Split will become effective at 12:01am, Eastern Time, on May 20, 2024. At such time, each 50 shares of issued and outstanding Common Stock will automatically be reclassified into one new share of Common Stock. The total number of shares of Common Stock authorized for issuance will remain at 100,000,000 shares. Proportional adjustments will be made to outstanding equity awards, warrants and convertible notes, and to the number of shares issued and issuable under the Company's stock incentive plans and certain existing agreements. No fractional shares will be issued in connection with the Reverse Stock Split. All fractional shares will be rounded up. The Reverse Stock Split will affect all common stockholders uniformly and will not alter any stockholder's percentage interest in the Company's equity. Blue Star's Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol "BSFC" and will begin trading on a split-adjusted basis when the market opens on May 20, 2024. The new CUSIP number for the Common Stock following the Reverse Stock Split will be 09606H309.

12:03 EDT AMC Entertainment falls -21.0% - AMC Entertainment is down -21.0%, or -$1.44 to $5.41.

12:02 EDT GameStop falls -30.5% - GameStop is down -30.5%, or -$14.89 to $33.86.

12:01 EDT Riskified rises 13.7% - Riskified is up 13.7%, or 73c to $6.09.

11:42 EDT Petrobras board approves early termination of CEO Jean Paul Prates - Petroleo Brasileiro S.A. announced: "Petrobras, in continuation of the Material Facts disclosed on 05/14/2024, informs that its Board of Directors, in a meeting held today, approved the early termination of Mr. Jean Paul Prates' mandate as CEO of Petrobras through negotiation, with effects from this date. With the termination of his mandate as CEO of the Company, Mr. Jean Paul submitted his resignation from the position of member of Petrobras Board of Directors. Due to the vacancy in the Presidency of the Company, the Chairman of the Board of Directors appointed the Executive Director of Corporate Affairs, Clarice Coppetti, as interim President of the company, based on Section 4 of article 27 of its Bylaws, until the election of the new CEO in accordance with article 20 of the Company's Bylaws. Additionally, the Board of Directors removed Mr. Sergio Caetano Leite from the position of Chief Financial and Investor Relations Officer, and appointed the current Finance Executive Manager, Mr. Carlos Alberto Rechelo Neto, as interim, until the election of a new CFO by the Board of Directors. Material facts deemed relevant will be promptly disclosed to the market." Reference Link

11:36 EDT Gulfstream Aerospace's Gulfstream G700 receives EASA certification - Gulfstream Aerospace Corp., a wholly owned subsidiary of General Dynamics, announced the all-new Gulfstream G700 has received European Union Aviation Safety Agency type certification, following the aircraft's Federal Aviation Administration type certification on March 29.

11:06 EDT Community Bank System changes corporate name to Community Financial System - Community Bank System announced that it has changed its corporate name to "Community Financial System, Inc." effective as of today. The name change reflects the Company's broader business model and mission in contributing to the prosperity of its community, including its clients, colleagues and shareholders by providing comprehensive financial services across its four main business lines. The Company's ticker symbol will not change and its common stock will start trading on the New York Stock Exchange as Community Financial System, Inc. on May 24, 2024.

10:16 EDT Netflix to stream live NFL games on Christmas Day, NFL announces - On Dec. 25, 2024, Netflix will be the global home of the NFL's two Christmas Day marquee games, the league announced. "Mark your calendar for Christmas Day in 2025 and 2026 when Netflix will be streaming at least one holiday game each year as part of this three-season deal," the NFL added. "Last year, we decided to take a big bet on live -- tapping into massive fandoms across comedy, reality TV, sports and more. There are no live annual events, sports or otherwise, that compare with the audiences NFL football attracts. We're so excited that the NFL's Christmas Day games will be only on Netflix," said Bela Bajaria, Netflix chief content officer. Reference Link

10:11 EDT Manhattan Associates announces Manhattan Active Maven GenAI solution - Manhattan Associates announced Manhattan Active Maven, a specialized Generative Artificial Intelligence solution built for customer service, along with Manhattan Assist, which adds GenAI capabilities to all Manhattan Active solutions. The company said it is applying this state-of-the-art technology to revolutionize consumer interactions, as well as enhancing how Manhattan's customers engage with their solutions. "GenAI is one of the most exciting technologies we've seen in years, and it promises to redefine customer service experiences," said Ellie Crawford, director of Product Management for Manhattan Associates. "Manhattan Active Maven and Manhattan Assist represent an exciting application of this technology in supply chain and commerce, delivering new levels of personalization, productivity, and cost-savings."

10:04 EDT B&G Foods rises 10.1% - B&G Foods is up 10.1%, or 86c to $9.40.

10:03 EDT Riskified rises 11.8% - Riskified is up 11.8%, or 63c to $5.99.

10:02 EDT Annovis Bio rises 14.0% - Annovis Bio is up 14.0%, or $1.17 to $9.53.

10:01 EDT Petrobras falls -9.5% - Petrobras is down -9.5%, or -$1.58 to $15.11.

10:01 EDT AMC Entertainment falls -16.9% - AMC Entertainment is down -16.9%, or -$1.16 to $5.69.

09:51 EDT AMC Entertainment falls -9.8% - AMC Entertainment is down -9.8%, or -67c to $6.18.

09:49 EDT GameStop falls -14.3% - GameStop is down -14.3%, or -$6.97 to $41.78.

09:48 EDT Bakkt rises 8.5% - Bakkt is up 8.5%, or 95c to $12.10.

09:47 EDT Riskified rises 11.8% - Riskified is up 11.8%, or 63c to $5.99.

09:43 EDT Yield10 Bioscience trading halted, volatility trading pause

09:41 EDT Sow Good Inc trading halted, volatility trading pause

09:38 EDT AMC Entertainment trading resumes

09:37 EDT Cheetah Net Supply Chain Service Inc trading resumes

09:36 EDT MMTec Inc trading halted, volatility trading pause

09:34 EDT Disney CEO sees streaming unit as double-digit margin business

09:32 EDT JLL agrees to acquire SKAE Power Solutions - JLL announced it has reached an agreement to acquire SKAE Power Solutions, a New York-based provider of data center technical and project management services. "This acquisition of SKAE enables JLL to provide solutions across the full data center lifecycle and adds significant technical depth to its existing offerings. The transaction is expected to close shortly, subject to customary closing conditions," the company stated. "SKAE will be key in scaling JLL's capacity to meet clients' needs and accelerating our abilities in data center management. Combining SKAE's regional expertise and talent with JLL's global, comprehensive suite of solutions will both complement and expand our technical services capabilities," said Sanjay Rishi, Americas CEO of Work Dynamics, JLL.

09:32 EDT GameStop trading halted, volatility trading pause

09:30 EDT Comstock Holding Companies trading halted, volatility trading pause

09:24 EDT Xylo: Charging Robotics, Make My Day deploy AI-based charging management system - Xylo Technologies announced that Charging Robotics as part of its collaboration with Make My Day, reached the final stages of development of their software for EV charging management in automatic car parks. The charging management system uses machine learning and artificial intelligence algorithms in an attempt to meet the growing shortage of electricity for EV charging. With the rise in EV adoption, there is growing concern that a given facility's available electricity supply will not be sufficient to fully charge all EVs parked in the typical automatic parking facility in the required time. In order to address this need, Charging Robotics and Make My Day jointly developed a charging management software that allows the wireless system in automatic car parks to prioritize the charge sequence for all present EVs and deliver the exact amount of electricity each EV needs.

09:17 EDT Capital Power provides redemption notice on Preferred Shares - Capital Power intends to redeem all of its 6,000,000 issued and outstanding 5.75% Cumulative Minimum Rate Reset Preference Shares, Series 11 on June 30, 2024 at a price of $25.00 per share for an aggregate total of $150 million, less any tax required to be deducted and withheld by the Company. As June 30, 2024 is not a business day payment of the Redemption Price will occur on July 2, 2024. As previously announced, the Company's Board of Directors has declared a quarterly dividend of $0.359375 per Series 11 Share payable on June 28, 2024 to shareholders of record as of June 17, 2024. This will be the final quarterly dividend on the Series 11 Shares.

09:15 EDT Churchill Downs opens Terre Haute Casino Resort Hotel - Churchill Downs announced the opening of its new 122-room hotel and event center at Terre Haute Casino Resort. CDI opened the 400,000-square-foot regional entertainment venue's casino floor on April 5, 2024 with 1,000 slot machines, 36 tables games, and a state-of-the-art sportsbook. "Terre Haute Casino Resort has already attracted thousands of visitors from the region to enjoy an unparalleled gaming experience," said Bill Carstanjen, CEO of CDI. "The opening of the new luxury hotel component furthers our commitment to bringing new vibrancy to Terre Haute with this premier entertainment destination and marks a significant milestone for Churchill Downs Incorporated."

09:14 EDT ZOOZ Power announces Cohen will assume role of Interim CEO - ZOOZ Power announced that subject to shareholder approval, Avi Cohen, Executive Chairman, will assume the role of Interim CEO, succeeding Boaz Weizer, who will step down effective June 1, 2024. ZOOZ has initiated a thorough search process to identify its next CEO to lead the company into the next phase of its growth. Avi Cohen will serve as Interim CEO until a new CEO is appointed. Eyal Bloom, Chief Revenue Officer, will assume the role of Interim CBO, Chief Business Officer, responsible for all outbound customer facing functions including sales, marketing and customer service. Ms. Ruth Smadja, Chief Financial Officer, will assume the role of Interim COO, Chief Operating Officer, responsible for all other functions including finance, operations and R&D.

09:12 EDT PacBio and Ambry selected by University of California and the GREGoR Consortium - Ambry Genetics, a subsidiary of REALM IDx, along with PacBio announced their companies' selection by the University of California, Irvine, or UCI, and the GREGoR Consortium to support the Pediatric Mendelian Genomics Research Center, or MGRC, program to better understand the underlying biology of rare diseases. The GREGoR Consortium is a National Institutes of Health-funded collaborative effort which aims to transform the landscape of Mendelian disease research by identifying the underlying genetic cause of rare disease in samples from individuals for whom prior genomic analysis did not yield answers. This ambitious research, among the largest programs of its kind, will use long-read sequencing technology to sequence and analyze up to 7,000 human whole genomes over three years, with a focus on developing new insights into rare disease etiology.

09:11 EDT Intapp selected by Jackson Walker to advance timekeeping practices - Intapp announces that Am Law 200 firm Jackson Walker selected Intapp's compliant timekeeping solution to advance the firm's timekeeping practices. The software uses Applied AI to automate time capture and compliance with client requirements, leading to improved client satisfaction.

09:09 EDT Taboola announces partnership with a360media - Taboola announced a partnership with a360media. a360media will utilize Taboola's suite of products to grow its audience, optimize user engagement, and drive revenue. Taboola will be implemented into various a360media sites including Us Weekly, Life & Style, InTouch, Soap Opera Digest, and First For Women, among others. a360media will incorporate Taboola Feed, a seamlessly integrated feed that provides readers with personalized multi-format content recommendations for an engaging experience into the publisher's family of news websites, on homepages and article pages. Taboola allows a360media to provide personalized user experiences across these touchpoints, optimizing content recommendations to improve user engagement.

09:09 EDT Nasdaq to enhance global market surveillance offering with generative AI - Nasdaq announced the new AI powered feature within its Market Surveillance technology solution that will significantly enhance the quality, speed, and efficiency of market abuse investigations performed by our clients. The solution leverages generative AI to streamline the triage and examination process involved in investigating suspected market manipulation and insider dealing, empowering regulator and marketplace clients to more effectively monitor and detect potential market abuse. During proof-of-concept testing, surveillance analysts estimated a 33% reduction in investigation time, with improved overall outcomes. This represents a substantial gain in investigation efficiency. Nasdaq is planning to leverage the generative AI enabled functionality for its U.S. equity market surveillance.

09:07 EDT LPL Financial: Tara Blair joins broker-dealer, RIA, custodial platforms - LPL Financial LLC announced today that financial advisor Tara Blair, CFP, CPA, has joined LPL Financial's broker-dealer, RIA and custodial platforms. She reported serving approximately $215 million in advisory, brokerage and retirement plan assets and joins LPL from Lincoln Financial. Based in Fort Worth, Texas, Blair has more than 25 years of experience in financial services following an initial career in public accounting. She built her wealth management practice from the ground up by building meaningful relationships and creating positive experiences for her clients. At Sage Private Wealth Services, Blair provides sophisticated estate, succession, investment and philanthropic strategies for affluent individuals, business owners and executives.

09:07 EDT CAVA opens 55K square-foot manufacturing facility in Verona, Virginia - CAVA announced the official opening of a new, state-of-the-art food production and packaging facility in Verona, Virginia, located two hours outside Washington D.C., in the heart of the Shenandoah Valley. As part of its ongoing work to build a scalable infrastructure to support its growth, the company made an initial investment of approximately $35 M in the facility, which manufactures CAVA's proprietary dips and spreads, including tzatziki, harissa, and Crazy Feta , as well as select dressings. Along with an existing facility in Laurel, Maryland, the Verona operation can support at least 750 restaurants and the expansion of CAVA's consumer packaged goods business. "CAVA Foods Verona is part of a vertically integrated model that supports our business now and over the long term. By centrally producing our dips and spreads, we reduce complexity in our restaurants, improve costs overall, and maintain the quality, consistency, and integrity of our chef-crafted recipes at scale," said Brett Schulman, Co-Founder and CEO. "We're excited to be part of the Verona community and grateful for our ongoing partnership with Augusta County and the Commonwealth of Virginia."

09:05 EDT Acurx reports results from meeting with FDA regarding ibezapolstat - Acurx Pharmaceuticals announced the successful outcome of an End-of-Phase 2 meeting with the FDA supporting the advancement of ibezapolstat for the treatment of C. difficile Infection into Phase 3 studies based on the recently completed Phase 2 clinical trial results. Key elements for the two Phase 3, non-inferiority, pivotal trials were confirmed and included agreement on the protocol design, patient population, primary and secondary endpoints, and size of the registration safety database. Based on FDA recommendations, and in anticipation of an EMA Scientific Advice Meeting, the primary efficacy analysis will be performed using a Modified Intent-To-Treat, or mITT, population consistent with EMA requirements. This will result in an estimated 450 subjects in the mITT population, randomized in a 1:1 ratio to either ibezapolstat or standard-of-care vancomycin, enrolled into the initial Phase 3 trial. The trial design not only allows determination of ibezapolstat's ability to achieve Clinical Cure of CDI as measured 2 days after 10 days of oral treatment, but also includes assessment of ibezapolstat's potential effect on reduction of CDI recurrence in the target population. In the event non-inferiority of ibezapolstat to vancomycin is demonstrated, further analysis will be conducted to test for superiority. The completed multicenter, open-label single-arm segment (Phase 2a) study was followed by a double-blind, randomized, active-controlled, non-inferiority, segment at 28 US clinical trial sites which together comprise the Phase 2 clinical trial. This Phase 2 clinical trial was designed to evaluate the clinical efficacy of ibezapolstat in the treatment of CDI including pharmacokinetics and microbiome changes from baseline and continue to test for anti-recurrence microbiome properties seen in the Phase 2a trial, including the treatment- related changes in alpha diversity and bacterial abundance and effects on bile acid metabolism. The completed Phase 2a segment of this trial was an open label cohort of up to 20 subjects from study centers in the U.S.

09:03 EDT Butterfly Network debuts specialty product, iQ+ Bladder in the U.S. - Butterfly Network introduced its first specialty product, iQ+ Bladder , now available for purchase in the United States. The bundled solution includes an iQ+ Bladder probe, streamlined software, compact rolling cart, tablet and power splitter, paired with premium assembly. Combined, the solution offers a fit-for-purpose ultrasound-based bladder scanner that helps nurses get automated bladder volume calculations, with 3D visualizations, in seconds..."The launch of the Butterfly iQ+ Bladder demonstrates Butterfly's commitment to extending our powerful Ultrasound-on-Chip(TM) technology into more markets where innovation is needed," said Joseph DeVivo, President, Chief Executive Officer, and Chairman of Butterfly Network. "With iQ+ Bladder, we move outside of our core point-of-care ultrasound market to better address the bladder scanning market, which has long awaited a more affordable, user-friendly solution. We listened to the unique needs of our nursing and bladder scanning customers and brought them a purpose-built, streamlined solution that meets their fast pace and high workload."

09:00 EDT HMN Financial trading resumes

08:57 EDT Charles & Colvard approves one-for-ten reverse stock split - Charles & Colvard announced that the Company's Board of Directors has approved a one-for-ten reverse split of the Company's common stock, no par value per share to be effective as of 12:01 a.m. Eastern Time on May 17. The Reverse Stock Split is intended to bring the Company into compliance with Nasdaq's $1.00 per share minimum bid price requirement for continued listing. The Company expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on May 17, 2024 with a new CUSIP number of 159765205. The ticker symbol for the Company stock will remain "CTHR." The Company's shareholders at a special meeting held on May 7, 2024, approved a proposal to amend the Company's Restated Articles of Incorporation to effect a Reverse Stock Split at a ratio within a range from any whole number between one-for-ten to one-for-fifteen, as determined by the Board of Directors in its sole discretion. The Company filed the Articles of Amendment to its Restated Articles of Incorporation with the North Carolina Secretary of State on May 14, 2024.

08:55 EDT Nuburu gets order for BlueScan solution from Blueacre Technology, no terms - Nuburu announced it has received a purchase order for its BlueScan solution from Blueacre Technology, a medical device manufacturer based in Dundalk, Ireland. The BL laser will be integrated by Blueacre with scan head optics to produce a versatile welding system for the manufacture of a range of precision medical devices. The order is a natural extension of the Company's market focus in the electric vehicle industry, next-generation computers, consumer electronics and communication 3C device manufacturing, and medical devices. The NUBURU blue laser addresses the need for a non-contact, high-speed process with low-to-no defects for manufacturing batteries and electric vehicles by replacing slower methods like ultrasonic and resistance welding, which represent multibillion-dollar equipment spent today due to their high cost of operations. It can work with copper, aluminum, titanium, and stainless steel, facilitate the manufacture of electric vehicle batteries, and address the tens of thousands of welds in an electric vehicle.

08:55 EDT Monogram Orthopaedics completes name change to Monogram Technologies - Monogram Orthopaedics announced its plan to merge its wholly owned subsidiary, Monogram Technologies with and into Monogram Orthopaedics Inc. In connection with this upstream merger, the current MT will cease to exist, and Monogram's business will continue as it is currently being conducted. Further, on May 15, 2024, the effective date of the merger, the Company will change its name to Monogram Technologies Inc., and its ticker will remain "MGRM."

08:54 EDT Solitario discovers three new multi-gram gold zones - Solitario Resources announced the discovery of three new zones of high-grade surface gold on its Golden Crest project. These zones are named Holland, Top Dollar and Wildcat. Assay results from reconnaissance rock sampling of outcrop, sub-crop and float yielded gold values as high as 57.9. 50.2. 42.7, 32.3 and 21.1 grams per tonne gold within the three zones. These three zones occur within an area approximately four-square kilometers in size between the Downpour and Sleeping Beauty targets. Assay results from these three zones total 203 samples and represent the final surface grab rock samples collected in the 2023 field season. Notable high-grade samples are presented in Table One below. Additionally, 51 of these samples contain greater than0.2 g/t Au while 27 contain greater than1 g/t Au. Chris Herald, President and CEO of Solitario, stated: "These are among the highest-grade samples collected during a first pass sampling program at a newly discovered target zone in the history of Golden Crest. It's amazing that after three field seasons, we are still discovering high-quality drilling targets displaying super high-grade gold values on the surface. We think there is a high probability that these three zones may coalesce into a single massive zone with additional work, just like the Geyser, Spur and Zig Zag zones came together. We now look forward to our drilling program at Golden Crest that is anticipated to begin in the first part of June.

08:53 EDT Brightline Interactive enters over $4M contract with Department of Defense - Brightline Interactive has entered into a one year task order contract in excess of $4 million with a Department of Defense entity to provide a spatial computing ecosystem enabling the integration of AI workflows and accelerated compute for a variety of defense use-cases.

08:51 EDT Oatly Group announces results of 2024 annual general meeting - Oatly Group announced the results of its Annual General Meeting of shareholders held on May 15, 2024. The AGM adopted, inter alia, the following resolutions: Adoption of the income statement and balance sheet, disposition regarding the Company's results and discharge from liability. The AGM adopted the Company's profit and loss account and the balance sheet as well as the consolidated profit and loss account and consolidated balance sheet. The AGM resolved, in accordance with the board of directors' proposal, that no dividend was to be distributed for the financial year 2023 and that the Company's result for the financial year 2023 was to be carried forward. The AGM also discharged the board of directors and the CEO from liability for the financial year 2023. The AGM resolved, in accordance with the nominating and corporate governance committee's proposal, that the number of members of the board of directors elected by the general meeting or in accordance with Oatly's articles of association shall be ten. The AGM resolved, in accordance with the nominating and corporate governance committee's proposal, to re-elect Eric Melloul, Ann Chung, Hannah Jones, Frances Rathke, Bernard Hours, Yawen Wu, Lai Shu Tuen-Muk and Xin Wang as members of the board of directors and to elect Gregory S. Christenson as a new member of the board of directors for a term ending at the AGM to be held in 2027. The AGM also resolved, in accordance with the nomination and corporate governance committee's proposal, to re-elect Eric Melloul as chairperson of the board of directors. The AGM resolved, in accordance with the remuneration committee's proposal, that the fee to each member of the board of directors, who is not employed by the Company or any of its subsidiaries, shall be USD 60,000, that the fee for the chairperson of the audit committee shall be USD 22,500 and that the fee for an ordinary member of the audit committee shall be USD 10,000. The AGM also resolved, in accordance with the remuneration committee's proposal, that the fee for the chairperson of the remuneration committee shall be USD 22,500, that the fee for an ordinary member of the remuneration committee shall be USD 10,000, that the fee for the chairperson of the nominating and corporate governance committee shall be USD 22,500 and that the fee for an ordinary member of the nominating and corporate governance committee shall be USD 10,000. The AGM also resolved that the fee for each ordinary employee representative shall be SEK 24,000. The AGM resolved, in accordance with the audit committee's recommendation, that the registered auditing company Ernst & Young Aktiebolag is re-elected as auditor for the period until the end of the next AGM. The AGM resolved, in accordance with the board of directors' proposal, to amend LTIP 2021-2026, entailing certain changes to allocation principles and certain terms and conditions relating to vesting of stock options and RSUs granted under LTIP 2021-2026. The changes in allocation principles aim to enable grants to current and future members of the executive management team, top key personnel, selected senior key personnel, selected mid-level personnel and other personnel, to achieve appropriate and proportional annual allocations over the duration of LTIP 2021-2026. The changes in allocation principles also aim to enable grants to a greater number of participants and to achieve appropriate and proportional annual allocations over the remaining duration of LTIP 2021-2026. The AGM also resolved, in accordance with the board of directors' proposal, to approve the transfer of treasury instruments issued in connection with the LTIP 2021-2026. The AGM further resolved, in accordance with the board of directors' proposal, to approve the exchange of outstanding stock options, entailing that senior key employees who were granted stock options between May 2021 and July 2023 will be given the opportunity to exchange their stock options for new RSUs with special vesting conditions, as the exercise price for each of the stock options is greater than the market value of an ADS in the Company. The stock option exchange program aims to incentivize the Company's senior key employees and create a retention benefit for the senior key employees while reducing the need to grant additional equity awards. The option exchange program also entails granting new RSUs with special vesting conditions but otherwise on materially the same terms and conditions as the previous RSUs granted under the LTIP 2021-2026. The AGM resolved to amend the resolution on issue of share awards to certain members of the board of directors of Oatly. As a result, the maximum number of share awards that may be granted to each participant in the board of directors LTIP is increased from 35,000 to 140,000 share awards annually. The limitation on the total value of share awards that may be granted to each participant is unchanged at USD 140,000 annually. In order to fulfil the commitments arising from the share awards, the AGM also resolved to authorize the Company to assign the warrants of Series 2021-B to a third party or in another way dispose of the warrants of series 2021-B.

08:49 EDT CloudMD announces go-private transaction with CPS Capital - CloudMD Software & Services and CPS Capital are pleased to announce that they have entered into an arrangement agreement pursuant to which CPS Capital has agreed to acquire all of the outstanding common shares of CloudMD for cash consideration of C$0.04 per Share. The Transaction is the culmination of a strategic and liquidity review that the Special Committee has been engaged in since July 2023, with the assistance of INFOR Financial Inc. Such review was necessary to address the Company's liquidity issues, which were largely the result of the number of acquisitions that the Company completed over the last four years. Although management of the Company was able to deliver on organic growth targets and strengthen the balance sheet while creating an ecosystem of care, the Company's forecasted liquidity issues impacted the Company's ability to remain a going concern. This is the result of the Company being unable to generate positive cashflow to support the business while making scheduled debt repayments, along with limited refinancing opportunities on commercially reasonable terms without onerous covenants, restricted business operations and forecasted growth initiatives. The Transaction provides the capital to support the Company's business with specific consideration to all of the Company's stakeholders and was the best alternative available to ensure the ongoing viability of the Company. If the Transaction is not completed, the Company does not expect that there will be an alternative that would provide any value to the holders of CloudMD's equity securities. The Transaction will be completed pursuant to a court-approved plan of arrangement under the Business Corporations Act. The Transaction will be subject to the approval of at least: 66 2/3% of the votes cast by shareholders; 66 2/3% of the votes cast by shareholders and optionholders voting as a single class; and 50% of the votes cast by disinterested shareholders at a special meeting of CloudMD securityholders expected to be held before the end of June 2024. In addition to securityholder approval, the Transaction is also subject to the receipt of certain regulatory, court and stock exchange approvals and other closing conditions customary in transactions of this nature. The Arrangement Agreement includes, among other things, non-solicitation covenants on the part of the Company and a right for the Purchaser to match any competing offer that constitutes a superior proposal. Under certain circumstances, the Purchaser is entitled to a $3 million termination fee or an expense reimbursement to a maximum of $1.5 million, and CloudMD is entitled to a $1.75 million reverse termination fee. The directors and executive officers of CloudMD, who collectively hold approximately 0.16% of the outstanding Shares and approximately 0.60% of the outstanding Shares and stock options collectively, entered into voting support agreements with the Purchaser to support the Transaction. Following completion of the Transaction, the Shares will be delisted from the TSX Venture Exchange, and the Company will apply to cease to be a reporting issuer in applicable provinces in Canada.

08:47 EDT Reliance Global announces acquisition of Spetner Associates - Reliance Global announced it has entered into a definitive agreement to acquire Spetner Associates. Ezra Beyman, CEO of Reliance, commented, "We could not be more thrilled to enter this definitive agreement to acquire Spetner which we are confident will prove to be the most significant acquisition in the Company's history. We expect that the addition of Spetner will more than double our current revenue and generate an Adjusted EBITDA of more than $4 million in 2024. Spetner is distinguished in its field, utilizing cutting-edge technologies that elevate it above its industry peers. This acquisition is monumental for Reliance, not just in scale but in its strategic fit within the Company's broader strategy. Its significance cannot be overstated-it is expected to more than double our current revenue, with Spetner projected to generate over $14 million in revenue during fiscal year 2024, bringing Reliance's revenue to approximately $28 million, while contributing meaningful EBITDA along with a high EBIDTA to revenue ratio. Spetner's suite of unique voluntary benefits programs and reach, serving over 75,000 individual lives, introduces great potential synergies for rounding out accounts through cross-selling for personal lines of insurance to be offered to those consumers through the RELI Exchange platform. While Spetner-BenManage was highly profitable on its own, integrating its offerings with our existing infrastructure should significantly ramp up our capabilities, effectively making the whole greater than the sum of its parts."

08:45 EDT Imunon announces abstract on Phase 2 study with IMNN-001 at ASCO meeting - IMUNON announces that an abstract describing a Phase 2 study with IMNN-001 plus bevacizumab and neoadjuvant chemotherapy in advanced epithelial ovarian cancer patients has been accepted for presentation at the American Society of Clinical Oncology, ASCO, annual meeting, to be held in Chicago from May 31st to June 4th. The abstract, titled "A phase II study evaluating the effect of IMNN-001 on second-look laparoscopy when administered in combination with bevacizumab and neoadjuvant chemotherapy in patients newly diagnosed with advanced epithelial ovarian cancer," will be presented on June 3rd at the Gynecologic Cancer session.

08:41 EDT Bausch Health announces results of 2024 Annual Meeting - Bausch Health Companies announced the results of its 2024 annual meeting of shareholders. Annual Meeting Results The 10 directors nominated at the Company's 2024 annual meeting of shareholders held on May 14, 2024, were elected by a vote of the shareholders. At the annual meeting of shareholders, shareholders also approved, in a non-binding advisory vote, the compensation of the Company's named executive officers, an amendment to the Company's 2014 Omnibus Incentive Plan to increase the number of common shares authorized for issuance thereunder, and appointed PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the Company's 2025 annual meeting of shareholders.

08:40 EDT Verint gets $4M deal with Australian Bank for 'new Verint TimeFlex Bot' - Verint continues to see contract wins and groundbreaking customer results for the new Verint TimeFlex Bot. Verint recently received a $$4M contract with a leading bank in Australia to deploy the Verint Open Platform's workforce management WFM and bot capabilities. The bank has been a long-time Verint customer and is now expanding with Verint to replace a WFM solution from another vendor and introduce the artificial intelligence AI powered Verint TimeFlex Bot for its 4,500 agents. Verint TimeFlex Bot will provide the bank's contact center agents with the flexibility to make unlimited schedule changes to reduce attrition and absenteeism while improving agent work/life balance. "This contract is testament to our open platform's unique ability to quickly deliver tangible AI business outcomes," says Verint's Jasen Williams, global vice president, corporate marketing. "The bot fits seamlessly into the customer's existing ecosystem and agents learn how to use the bot within minutes. The result is faster AI business outcomes including improved employee experiences and lower labor costs."

08:38 EDT Genasys receives $2.7M U.S. Navy Order for LRAD maritime systems - Genasys announced a $2.7M LRAD systems order from the U.S. Navy. The order is part of the Navy's ongoing replacement of first generation LRADs with new, upgraded long range communication LRAD 1000Xi systems. "LRAD systems have enhanced Navy ships' over-the-water communications and self-protection for more than 20 years," said Richard Danforth, Chief Executive Officer of Genasys. "LRAD provides operators more time and distance to determine the intent of potential threats not responding to radio calls and to initiate and scale escalation of force protocols accordingly."

08:37 EDT Atossa announces last patient, last dose in Phase 2 Karisma-Endoxifen trial - Atossa Therapeutics announced that the last patient in the Company's Karisma-Endoxifen clinical trial received their final dose of study medication. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The Karisma-Endoxifen study, which fully enrolled in November 2023, is a 240-person Phase 2 clinical trial investigating (Z)-endoxifen in premenopausal women with measurable mammographic breast density. "Completing dosing of the final patient in the Karisma-Endoxifen study is an important milestone for Atossa and our robust (Z)-endoxifen development program, which includes five ongoing Phase 2 studies," said Steven Quay, M.D., Ph.D., Atossa's President and Chief Executive Officer. "We look forward to seeing the breast density reduction data in the coming months and sharing it with regulatory authorities as it will allow us to further progress plans for a potential Phase 3, registrational study."

08:36 EDT PaxMedica files Nasdaq delisting appeal notice - PaxMedica announced it has timely filed a formal notice of appeal with the Nasdaq Office of Appeals and Review to reverse the decision of a Nasdaq Hearings Panel to delist the Company from Nasdaq. Following receipt of notification from Nasdaq on April 30th, PaxMedica determined to appeal the decision and intends to maintain that the Hearings Panel did not consider sufficiently or appropriately crucial aspects of PaxMedica's recent achievements and ongoing actions to regain compliance with all applicable requirements for continued listing. PaxMedica has retained Jacob Frenkel, Dickinson Wright, PLLC as its lead counsel in the appeal, working with the consulting firm that interacted previously with the Hearings Panel. Howard Weisman, CEO of PaxMedica, commented, "We are seeking a reevaluation of Nasdaq's recent action based on new developments that underscore our ongoing progress and commitment to addressing global health challenges. Notably, following our announcements on the completion of registration lots of PAX-101 in mid-April, the Company just submitted a briefing book for an important FDA Type C meeting scheduled for June 27th, during which we will present key updates on our plans for NDA submission later this year. We believe this, as well as our financing plans, which we made known to the Hearings Panel, support persuasively our arguments to appeal and restore trading on Nasdaq."

08:34 EDT TC Biopharm announces availability of TCB008 in its compassionate use program - TC BioPharm announced that the company's lead therapeutic TCB008 will be available to patients via a newly launched compassionate use program in the UK. Compassionate use refers to the prescription of unlicensed medicinal products to treat a patient in instances where their individual clinical needs cannot be met with the available licensed treatments. Patients enrolling in these clinical trials must meet specific entry criteria, both to protect vulnerable patient populations and ensure the validity of study data. These data must be reviewed and approved by regulatory agencies before products can be marketed as licensed medicinal products for patient treatment. Access to TCB's cell therapy products through the compassionate use program will provide medical practitioners with treatment options for patients who are ineligible to access experimental treatments through ongoing clinical trials.

08:32 EDT Taoping reports 25% y/y increase in April contract revenue - Taoping reported a total contract revenue value of approximately $2.9M for the month of April 2024, representing an increase of 25% compared to the month of April 2023. The company highlighted that its impressive growth was driven by its commitment to innovation, as evident by the increased demand for its wide array of AI-based products, including its Smart City solutions.

08:31 EDT Ultra Clean appoints Harjinder Bajwa as COO - Ultra Clean Holdings announced that it has appointed Harjinder Bajwa as COO, effective June 10. Bajwa will be based in Singapore. Bajwa brings 30 years of global operations expertise, including strategy development and execution, operations improvement and quality control, lean manufacturing and cost management. Most recently, Harjinder was the COO for Reconext, a leading provider of aftermarket lifecycle services for electronics. Prior, he held various roles with Flex, Ltd. for 26 years. From 2011 to 2021, he was the Senior Vice President, Global Operations of the High Reliability Solutions business unit, where he oversaw more than 40 sites in the Americas, Asia and Europe, and significantly grew the business unit's revenue and operating profits. Mr. Bajwa holds a B.S. in Mechanical Engineering from Panjab University and a M.S. in Engineering from San Jose State University. He has also completed executive development programs at the Massachusetts Institute of Technology and Stanford University.

08:28 EDT Victory Square Technologies provides corporate update - "2023 was a year of continued growth and new opportunities for Victory Square," said Shafin Diamond Tejani, CEO. "And, this momentum has continued in 2024, with a number of exciting catalysts on the horizon. Since 2017, we've evaluated over 1000 companies & startup ideas, of which 25 have made the cut. We have a healthy balance sheet, significant assets and have built a pipeline of new opportunities," said Tejani. Revenue for the year ended December 31, 2023, was $12,055,070 compared to $5,929,096 for the corresponding prior year period.

08:25 EDT FTC Solar announces new sales, leadership appointments - FTC Solar announced new leadership appointments and an expanded sales leadership team designed to enhance customer experience and success while supporting global sales and strategic growth. The leadership appointments include: Patrick Cook, to Senior Vice President, Capital Markets and Business Development. Alberto Echeverria, to Senior Vice President, International Sales. Tamara Mullings, to Senior Vice President, North American Sales.

08:24 EDT Immutep presents data from safety lead-in Phase of AIPAC-003 at ESMO Beast 2024 - Immutep announces efficacy, safety, and pharmacodynamic data from the safety lead-in of the AIPAC-003 Phase II/III trial presented at the European Society for Medical Oncology, ESMO, Breast Cancer 2024 Congress. This lead-in represents the first ever 90mg dosing of eftilagimod alpha, a soluble LAG-3 protein and MHC Class II agonist, given in combination with weekly paclitaxel. The poster titled "Testing a higher dose of eftilagimod alpha in metastatic breast cancer patients receiving weekly paclitaxel in AIPAC-003" details positive results in six metastatic breast cancer patients, who exhausted endocrine therapy including cyclin-dependent kinase 4/6 inhibitors. The data shows a confirmed 50% overall response rate, including one complete response and two partial responses, and a 100% disease control rate, with three patients having stable disease as best overall response per RECIST 1.1. The lead-in has also shown that the first-ever 90mg efti dosing in combination with weekly paclitaxel continues to be well tolerated with a favourable safety profile

08:23 EDT PharmaTher's Sairiyo submits CTA for Phase 1 study of cepharanthine - PharmaTher Holdings announced Sairiyo Therapeutics has submitted to the Australian Human Research Ethics Committee for review and potential approval to initiate a Phase 1 clinical study of Sairiyo's patented reformulated enteric coated version of orally bioavailable cepharanthine as a potential treatment for infectious diseases and oncology The Phase 1 study entitled "Phase 1 Open-label, Single Dose, 3-Way Cross-Over Trial to Assess in Healthy Volunteers the Bioavailability and Pharmacokinetics Of 30 mg and 60 mg Oral Enteric Coated Capsules of Cepharanthine Dihydrochloride in Comparison to 6 mg Oral Cepharanthine Dihydrochloride Tablets", if approved by the Australian regulators in June 2024, will be a first-in-human study of PD-001. Sairiyo's wholly-owned subsidiary in Australia, Sairiyo Therapeutics Australia Pty Ltd., is the sponsor of the Study. In pursuit of its clinical strategy for PD-001, Sairiyo aims to conduct its first-in-human clinical study of PD-001 in Australia to capitalize on drug development incentives in Australia, which could earn a 43.5 percent rebate from the Australian Federal Government's Research and Development tax incentive program. Upon completion of the clinical study, Sairiyo intends to submit an Investigational New Drug application for PD-001 to the U.S. Food and Drug Administration to commence Phase 2 and Phase 3 clinical trials in the United States.

08:22 EDT Celldex announces first patient dosed in Phase 2 study of barzolvolimab - Celldex Therapeutics announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis. "Prurigo nodularis is a miserable disease and treatment options are desperately needed that offer early and durable relief by both reducing the relentless itching associated with the disease and allowing for healing of the painful lesions that are the hallmark of PN," said Diane C. Young, M.D, Senior Vice President and Chief Medical Officer of Celldex Therapeutics. "In our Phase 1b PN study, with just a single dose of barzolvolimab, we demonstrated remarkable clinical results. We are very excited to see what multiple doses of barzolvolimab may offer patients in this important Phase 2 study."

08:21 EDT Cero Therapeutics says 'diligently' completing IND-enabling work - CERo Therapeutics Holdings provides shareholders with a corporate update reviewing activities since its entering the public market. CERo Chairman and CEO Brian G. Atwood comments, "CERo has undergone significant transformation since the founding of this small private company dedicated to exploring the potential of engineered T cells, to a merger with SPAC Phoenix Biotech Acquisition Corporation, with multiple preclinical milestones along the way. The June 2023 initiation of the merger, followed by the February 2024 de-SPAC has positioned the Company as an operating Nasdaq-traded entity, which we believe has been in the highest interest of all our various shareholders. In the meantime we have been diligently completing the pre-clinical studies and documentation tasks necessary to initiate clinical trials after acceptance of an Investigational New Drug Application with the FDA. In March 2024, we announced the publication of "Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia" in Clinical Cancer Research, a journal of the American Association for Cancer Research. The paper is a composite of preclinical studies analyzing what we established as our lead clinical candidate CER-1236 in targeting Acute Myelogenous Leukemia tumor cells from human patients, and the candidate's killing effects on these tumor cells. These outcomes are a snapshot of a previous paper the Company published in May 2023, "Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic antitumor responses and phagocytic uptake of tumor associated antigen for T cell cross-presentation." Published in Molecular Therapy, this was the first published review of our mechanism of action, for which the subsequent paper provided additional evidence in another cancer, AML. We are now diligently completing our IND-enabling work, from toxicology studies to completing manufacturing runs to meet cGMP standards, all in the interest of submitting an application to the FDA in the near term. The additional studies will also likely result in submissions to peer reviewed venues such as medical conferences and publications to help gain additional validation of this extensive work. We anticipate providing status updates to our shareholders, including presentations at upcoming investor conferences, potential growth of our intellectual property portfolio, and progress on other programs beyond AML, as it is made and through other methods of communication, as appropriate. In the meantime, we remain grateful to our shareholders and to the scientific community for its embrace of what we believe is game changing science with significant potential to alter the way we treat cancer," concluded Mr. Atwood.

08:19 EDT Entera Bio appoints Wagman as Key Clinical Advisor, SAB member - Entera Bio announced the appointment of Rachel Wagman, MD, FACE, FACP, as Key Clinical Advisor and Member of its Scientific Advisory Board, SAB. Dr. Wagman brings more than 20 years of metabolic bone disease and women's health research and drug development experience to Entera.

08:18 EDT Soleno Therapeutics launches initiative in honor of PWS Awareness Day - Soleno Therapeutics launched an initiative in honor of Prader-Willi Syndrome, PWS, Awareness Day. The campaign aims to raise awareness of PWS and celebrate individuals living with this life-threatening disease. "At Soleno, we are deeply committed to making a meaningful difference in the lives of individuals with Prader-Willi syndrome," said Dr. Anish Bhatnagar, Chief Executive Officer of Soleno Therapeutics. "This campaign aims to highlight the resilience and beauty within the PWS community, and we hope it will inspire greater awareness, understanding, and support for those living with this rare disease."

08:16 EDT Celestica introduces four new enterprise access networking switches - Celestica launched four new networking switches designed to help enterprises meet the performance and connectivity demands of modern businesses. Expanding on Celestica's portfolio of networking switches, the four new switches include: ES1000 - 1GbE, 24 or 48 port, secured access switch; ES1010 - 1GbE, 48 port, secured access switch; ES1050 - 1GbE / 2.5GbE, 48 port, secured, access switch; EG1050 - 1GbE / 2.5GbE, 48 port, secured gateway switch, with concurrent Wi-Fi & 5G / LTE. All four Ethernet switches come in a 1U form factor for organizations looking for compact, secure, scalable and performative networking; a range of memory and processor options; redundant, field-replaceable fans and power supplies for high reliability; and up to 90 Watt POE++ on any port. Along with Celestica's entire portfolio of networking switches, these latest additions support SONiC

08:14 EDT Reviva announces enrollment update for OLE study on brilaroxazine - Reviva Pharmaceuticals announced an enrollment update to the ongoing 1-year open-label extension, OLE, study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia. "We are very pleased with the pace of enrollment of our OLE study, which is progressing well across sites in the USA, Europe and Asia. As of mid-May we have 358 patients enrolled in the study, 223 patients that are currently on treatment, over 90 patients have completed 6-9 months, and 23 patients who have completed one year of treatment," said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. "Importantly, we are close to gathering long-term safety data in 100 patients with one year of treatment, which is a requirement for our planned New Drug Application submission to the Food and Drug Administration expected in Q4 2025. To date, brilaroxazine has been generally well tolerated across patients with acute and stable schizophrenia in the OLE study. We look forward to reporting topline 12 months long-term safety data in the fourth quarter of this year."

08:12 EDT VCI Global provides preliminary funding for Saudi project - VCI Global Limited announces plans to facilitate the Capital Raising of no less than $210M for Magnum Mining & Exploration Limited through its subsidiary, V Capital Consulting Limited, VCCL. The agreement with VCCL and 2x1.Digital Private Limited is to undertake a capital raising of no less than US$210 million to advance Magnum's Green Pig Iron Project in Saudi Arabia. Magnum is to receive no less than $10 million as working capital, and the remaining amount, no less than $200 million, is to be provided as 50% of the capital for the Midmetal HIsmelt plant. The remaining 50% funding for the Midmetal HIsmelt plant will be matched by the Saudi Investment Development Fund. Investors participating in the Capital Raising will receive fully paid ordinary shares in Midmetal in proportion to their participation in the Capital Raising up to a total aggregate interest in Midmetal of 50%; and, subject to Magnum's shareholder approval, fully paid ordinary shares in Magnum in proportion to their participation in the Capital Raising up to a total aggregate interest in Magnum of 19.99%.

08:11 EDT Treasure Global remains 'optimistic' about growth prospects - Looking ahead to the fourth quarter of fiscal year 2024, Treasure Global remains optimistic about its growth prospects and strategic initiatives. The Company believes it is well-positioned to capitalize on the economic growth of Southeast Asia, leveraging its innovative solutions and market expertise to expand further into key markets. Through continuous efforts to reorient its strategic planning towards strengthening and expanding into higher profit margin channels, Treasure Global remains steadfast in fortifying its position, reducing net losses, and focusing on bolstering gross profit margins to enhance overall financial performance. By strategically investing in these areas and remaining committed to excellence, Treasure Global aims to drive sustainable growth and create long-term value for its shareholders.

08:07 EDT Eli Lilly announces retirement of Chief Ethics and Compliance Officer Weems - Eli Lilly and Company announced that Alonzo Weems, executive vice president of enterprise risk management and Chief Ethics and Compliance Officer, and a member of Lilly's Executive Committee, will retire after 27 years of service with the company, effective Dec. 31. Weems will continue to serve in his role while the company conducts an internal and external search for a chief ethics and compliance officer. Weems began his Lilly career in 1997 as an attorney in the global medical and regulatory affairs legal group. Throughout his career, he has held important leadership roles, including general counsel for Lilly Canada, general counsel for Lilly USA and the Biomedicines and Diabetes business units, and vice president and deputy general counsel for the corporate legal functions prior to assuming his current role. Ethisphere recognized Lilly as one of the World's Most Ethical Companies for the eighth year in a row in 2024, underscoring Weems' pivotal role in championing sustained excellence in ethical practices across the organization.

08:05 EDT SunCar Technology and Zeekr extend collaboration - SunCar Technology Group (SDA) announced an extended collaboration with Zeekr Intelligent Technology Holding (ZK), a premium electric automobile brand under Zhejiang Geely Holding Group. This partnership will utilize SunCar's cutting-edge intelligent insurance service platform to deliver innovative solutions to Zeekr's customers across China, representing the latest expansion and advancement for SunCar within the insurance sector. The enhanced collaboration with Zeekr highlights SunCar's ongoing expansion and inventive strides within the insurance industry. The collaboration blends digital and traditional insurance services by integrating SunCar's state-of-the-art intelligent insurance platform with its robust cloud infrastructure.

08:03 EDT Kimberly-Clark appoints Patricia Corsi as Chief Growth Officer - Kimberly-Clark announced that Patricia Corsi will join Kimberly-Clark as Chief Growth Officer, effective July 1. She succeeds Alison Lewis, who has decided to retire from the company after 35 years in the consumer products industry, including the last five years at Kimberly-Clark. Lewis will serve in an advisory role until September 1, 2024, to ensure a smooth transition. Corsi joins Kimberly-Clark from Bayer Consumer Health, where she served as Chief Marketing, IT and Digital Officer and led a broad set of brand and commercial teams and oversaw the IT and Digital organizations. Among her accomplishments at Bayer, Corsi led the company's margin accretive innovation pipeline, with new products representing the majority of Bayer Consumer Health's sales growth over a five-year period. In 2023, she was named one of the Top Chief Marketing Officers by Cannes Lions, inducted into the World Advertising Federation (WFA) Marketer of the Year Hall of Fame, and recognized as an Adweek Brand Genius.

08:01 EDT Solid Biosciences expects cash to fund strategic priorities into 2026 - Solid had $206.1 million in cash, cash equivalents, and available-for-sale securities as of March 31, 2024, compared to $123.6 million as of December 31, 2023. The Company expects that its cash, cash equivalents, and available-for-sale securities as of March 31, 2024, will enable it to fund key strategic priorities into 2026.

07:57 EDT Forza X1 optimizes workforce to align with production needs - The Company is enacting the following key measures: "Capital Expenditure Reduction: With the exception of our new facility, capital expenditures have been significantly curtailed, focusing only on essential maintenance and strategically critical projects. Non-essential development has been postponed or re-evaluated based on stringent ROI analyses. Workforce Optimization: Although a difficult decision, we have optimized our workforce to align with current production needs and financial realities. This includes a temporary freeze on hiring and, regrettably, reductions in areas where the workload has decreased. These measures are designed to preserve as many jobs as possible while maintaining financial viability. Expense Management: We are scrutinizing all expenses, from administrative to marketing, ensuring that only those that are essential and offer clear value are maintained or increased. This has also involved renegotiating contracts and seeking better terms from suppliers to reduce costs without compromising quality."

07:51 EDT India Fund announces results of Rights Offering - The India Fund announced the completion of its transferable rights offering . The Offer commenced on April 19, 2024, and expired on May 14, 2024. The Offer entitled Rights holders to subscribe for shares of the Fund's common stock of beneficial interest, par value $0.001 per share. The final subscription price was $17.75 per share of Common Stock and was determined based upon 93% of the Fund's net asset value per share of Common Stock at the close of trading on the New York Stock Exchange on the Expiration Date, which was greater than the formula of 92.5% of the average of the last reported sales price of a share of Common Stock on the NYSE on the Expiration Date and each of the four immediately preceding trading days. The Rights exercised in the Offer will result in the issuance and sale of 6,237,159 shares of Common Stock, and gross proceeds of the Offer are expected to be approximately $110 million. The shares of Common Stock subscribed for will be issued after completion of the allocation of the over-subscription shares of Common Stock and receipt of all shareholder payments. The shares of Common Stock are expected to be issued on or about May 21, 2024.

07:47 EDT Aya Gold & Silver maintains 2024 guidance - 2024 guidance remains unchanged.

07:44 EDT M&T Bank expands use of nCino with adoption of credit monitoring solution - nCino (NCNO) announced that M&T Bank Corporation (MTB) is expanding its use of the nCino platform and integrating nCino's Continuous Credit Monitoring Solution into its operations. The solution is powered by nIQ and leverages Rich Data Co's, RDC, AI decisioning platform. nCino's Continuous Credit Monitoring Solution leverages RDC's explainable AI platform and is designed to bring transparency to every decision, giving M&T more comprehensive insights into cash flow health, credit risk, and lending opportunities at both the customer and portfolio levels. This will enable M&T to detect more early warning signs and have access to additional data when making decisions throughout the customer relationship lifecycle.

07:43 EDT Lilium welcomes KfW due diligence undertaking - The Federal Government of Germany and the Free State of Bavaria have commissioned the state development bank KfW in Frankfurt to conduct due diligence on Lilium as part of the customary state support process. Once the diligence is completed and results satisfactory, Lilium expects to receive guarantees from the Federal Government and the Free State of Bavaria as security for a KfW loan, the exact amount of which is yet to be determined. "We would like to thank those responsible in Berlin and Munich for their decision and the constructive cooperation over the last few weeks," said Lilium CEO Klaus Roewe. "We expect due diligence to be swift as transparency is a daily routine for us as a listed company."

07:41 EDT Verrica Pharmaceuticals entered into amendment to license agreement with Torii - Verrica Pharmaceuticals announced that it has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH for the treatment of common warts. "We are pleased to announce this significant amendment to our license agreement with Torii Pharmaceutical to advance YCANTH into a global pivotal Phase 3 clinical trial for the treatment of common warts," said Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals. "Torii has been an outstanding partner in the development of YCANTH for molluscum contagiosum, and we look forward to our continued collaboration to progress YCANTH through a pivotal global Phase 3 clinical trial for common warts, which represents the single largest and most underserved patient population in all of dermatology. If positive, the data from this global Phase 3 clinical trial would not only potentially allow Verrica to submit a sNDA in the U.S. seeking FDA approval for the use of YCANTH for the treatment of common warts, but may also be utilized by Verrica to seek future marketing authorizations in territories outside the U.S. and Japan, including potentially within the European Union."

07:39 EDT BridgeBio reports inducement grants under Nasdaq listing rule - BridgeBio Pharma announced that on May 9, 2024, the compensation committee of BridgeBio's board of directors approved equity grants to 24 new employees in restricted stock units for an aggregate of 97,557 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on May 16, 2025, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan. The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio's board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

07:38 EDT Bowman Consulting selected by ADOT to provide engineering, oversight services - Bowman Consulting has been selected by the Arizona Department of Transportation, or ADOT, to provide engineering and oversight services related to the construction of pedestrian and bicycle grade separation at Arizona State University's (ASU) Tempe campus. Bowman, serving as the prime engineering contractor, will lead the project in collaboration with Jacobs and SmithGroup. The Company will develop an advanced utility relocation (AUR) plan, coordinate public art integration and develop alternative alignments, preliminary cost estimates and 360-degree renderings while engaging the public and key area stakeholders throughout the project.

07:28 EDT Bolt Biotherapeutics ceases BDC-1001 development, cuts 50% of staff - Bolt Biotherapeutics last night announced a strategic prioritization as well as changes to its leadership team. The company will focus its pipeline on its proprietary agonist antibody targeting Dectin-2 and its next-generation Boltbody ISAC programs, continue to support its collaborations with Genmab and Toray, and reduce its workforce by approximately 50%. As part of the refocusing, Willie Quinn has been appointed Chief Executive Officer, Grant Yonehiro has been promoted to Chief Operating Officer, Dawn Colburn has been promoted to Senior Vice President, Clinical Development. Michael Alonso has been promoted to Senior Vice President, Research and Sarah Nemec is being appointed Principal Accounting. Following a strategic review, Bolt determined that its BDC-1001 program will not meet its pre-defined success criteria, and the company will therefore be focusing resources on its next-generation ISAC programs. Bolt expects to extend its cash runway into the second half 2026, funding the completion of the BDC-3042 Phase 1 trial and also enabling the delivery of clinical data for next-generation ISAC BDC-4182. The stock in premarket trading is down 30% to 93c.

07:25 EDT Dorman Products expands catalog of repair solutions - Dorman Products is announcing the release of hundreds of new aftermarket automotive components and assemblies. The new products add to an expansive catalog of more than 120,000 SKUs, a depth and diversity of coverage offering millions of new sales and repair opportunities for customers throughout North America. Noteworthy among the hundreds of releases are ten Dorman OE FIX innovations, adding to this flagship line of parts designed to save time, money and labor. More than 2,000 OE FIX products offer a level of performance and convenience that customers may not be able to obtain from a dealership.

07:23 EDT Olema Oncology announces new data on palazestrant with ribociclib - Olema Pharmaceuticals announced interim results from an ongoing Phase 1b/2 clinical study of palazestrant in combination with CDK4/6 inhibitor ribociclib for the treatment of ER+/HER2- metastatic breast cancer. These results, as of the data cut-off of March 13, 2024, will be presented on May 16, 2024, in a poster session at the 2024 ESMO Breast Cancer Annual Congress. The poster, titled "A Phase 1b/2 Study of Palazestrant in Combination with Ribociclib in Patients with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Advanced and/or Metastatic Breast Cancer", highlighted that: Across 50 treated patients, the combination of up to 120 mg of palazestrant with the full and approved dose of 600 mg of ribociclib daily was well tolerated, with no new safety signals or enhancement of toxicity and an overall safety profile consistent with the established safety profile of ribociclib plus an endocrine therapy. Palazestrant did not affect ribociclib drug exposure and ribociclib had no clinically meaningful effect on palazestrant drug exposure. Promising preliminary efficacy was observed to date with a clinical benefit rate of 85% across all CBR-eligible patients, 83% in ESR1-mutant patients, 86% in ESR1-wild-type patients, and 83% in prior CDK4/6 inhibitor patients. Partial responses were observed in five patients through the data cut-off among 23 response-evaluable patients. Findings from this study support the continued clinical development of palazestrant in combination with ribociclib for the first-line treatment of ER+/HER2- advanced or metastatic breast cancer.

07:22 EDT TFF Pharmaceuticals provides update on TFF TAC Phase 2 trial - TFF Pharmaceuticals provided an update from the Company's ongoing Phase 2 trial of Tacrolimus Inhalation Powder, TFF TAC, for the prevention of lung transplant rejection. Program update: The Phase 2 study now has 10 patients enrolled and 6 out of 6 patients who completed the 12-week treatment period with TFF TAC have chosen to remain on the therapy by proceeding to the safety extension phase. 1 patient has been treated for over a year and 3 additional patients have been treated for more than 6 months. PK data from first patient cohort indicate that TFF TAC dosing results in reduced systemic variability of tacrolimus; the systemic tacrolimus trough to peak concentration swings that occur with oral tacrolimus are not present with TFF TAC, which is predicted to reduce the risk of acute rejection and systemic toxicities such as chronic kidney disease, respectively. Patients on TFF TAC have provided anecdotal feedback to investigators noting a reduction in headaches, overall improvements in wellness, and/or ease of use in administration

07:21 EDT Cibus applauds CFIA on updated feed guidelines for new plant varieties - Cibus applauds the Canadian Food Inspection Agency, CFIA, Animal Feed Division's publication of its updated feed guidelines clarifying requirements for new plant varieties developed using applications of gene editing. The guidelines confirm that CFIA intends to follow a product, rather than process-based, approach to regulation and adds Canada to a growing list of countries that have endorsed policies that will regulate Cibus' Rapid Trait Development System gene editing technologies similar to conventional breeding.

07:19 EDT Ree Automotive announces Penske Truck Leasing to offer Powered by REE EVs - REE Automotive (REE) announced that Penske Truck Leasing (PAG) will begin to offer Powered by REE EVs to its customers interested in electrifying their fleets for demos and orders, adding further momentum to REE's current $50 million order book value. "We are looking forward to adding REE's by-wire vehicle to our electric truck lineup and giving our fleet customers the opportunity to demo the vehicle and experience the technology firsthand," said Paul Rosa, Senior Vice President of Procurement & Fleet Planning at Penske.

07:17 EDT OTC Markets Group welcomes Butler National to OTCQX - OTC Markets Group announced Butler National Corporation has qualified to trade on the OTCQX Best Market. Butler National Corporation upgraded to OTCQX from the OTCQB Venture Market.

07:16 EDT Krystal Biotech to present preclinical data on KB407, KB408 - Krystal Biotech announced today that the Company will be presenting new preclinical data on respiratory genetic medicine candidates KB407 and KB408 at the American Thoracic Society 2024 International Conference being held from May 17-22, 2024 in San Diego, California. KB407 and KB408 are modified, replication-defective, non-integrating HSV-1 vectors formulated for inhaled delivery to the lung via nebulization. KB407 encodes two full-length copies of cystic fibrosis transmembrane conductance regulator and is under investigation for the treatment of cystic fibrosis irrespective of underlying patient mutation. KB408 encodes two full-length copies of alpha-1 antitrypsin and is under investigation for the treatment of alpha-1 antitrypsin deficiency. Both KB407 and KB408 are being evaluated in ongoing Phase 1 studies. Data presented at ATS will include new preclinical data related to KB407 transduction of fully differentiated, patient airway epithelial cell-derived apical out airway organoids and production of full-length and fully glycosylated CFTR, as well as an overview of KB408 IND-enabling studies conducted to support initiation of the ongoing Phase 1 SERPENTINE-1 study in patients with AATD.

07:15 EDT aTyr Pharma to present poster of efzofitimod's mechanism of action - aTyr Pharma announced that the company will present data for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society 2024 International Conference, which is scheduled to take place May 17 - 22 in San Diego, CA. The poster presents findings demonstrating that by selectively binding neuropilin-2, a cell surface receptor upregulated at active sites of inflammation, most notably on myeloid cells, efzofitimod modulates the differentiation of monocyte-derived macrophages in healthy donors and ILD patients, resulting in a unique phenotype with reduced inflammatory potential. Additionally, the data further validates the discovery of NRP2 as an important new immune target, with higher expression of NRP2 detected on circulating monocytes from ILD patients compared to healthy donors and on macrophages within pulmonary sarcoidosis granulomas and other tissues from chronic inflammatory diseases. These findings suggest that efzofitimod may have broad therapeutic potential in diseases where myeloid cells play a central role in pathology, including ILD.

07:07 EDT Oncolytics announces preliminary collaboration with GCAR - Oncolytics Biotech announced that it has entered into a preliminary collaboration with the Global Coalition for Adaptive Research. The purpose of the preliminary collaboration is to commence planning activities for the evaluation of pelareorep in the treatment of first-line metastatic pancreatic ductal adenocarcinoma as part of GCAR's anticipated master protocol for metastatic pancreatic cancer. Activities are currently underway to finalize the seamless Phase 2/3 master protocol design that will evaluate multiple investigational therapies for the treatment of pancreatic cancer. An intent of the study is to produce registration-enabling data.

07:04 EDT Atai Life Sciences promotes Srinivas Rao to Co-EO - atai Life Sciences announced a transition in its leadership. Florian Brand, Co-Founder and current CEO, will step down as CEO by the end of this year. Co-Founder Srinivas Rao, currently the Chief Scientific Officer, will be promoted to Co-CEO effective June 1, and intends to assume the role of CEO by the end of the year subject to appointment as required by local law. Rao brings over 24 years of knowledge and experience from diverse biotechnology and pharmaceutical roles, having held the titles of Chief Scientific, Medical, or Executive Officer at companies ranging from venture-backed startups to vertically integrated, publicly traded pharmaceutical companies.

07:00 EDT Riskified approves additional $75M share repurchase program - The Board of Directors authorized the repurchase of an additional $75M of the Company's ordinary shares, subject to the completion of required Israeli regulatory procedures. Assuming completion of the required Israeli regulatory procedures, our total outstanding aggregate repurchase authorization is approximately $92M, as of May 10th.

06:41 EDT ReNew Energy Global signs MoU with Societe Generale - ReNew announced that it has signed a Memorandum of Understanding, or MoU, with Societe Generale, to support the financing and development of the Company's various strategic energy transition projects both in India and globally. Under the MoU, which references up to $1B of support over the next three years, primarily including debt financing and advisory solutions, both parties will leverage their respective expertise to strengthen the collaboration on utility-scale energy projects including solar, wind, complex renewables, green hydrogen, energy storage and solar modules manufacturing.

06:33 EDT Dynatrace announces $500M share repurchase program - Dynatrace announced that its Board of Directors has authorized a share repurchase program for up to $500M of common stock. Share repurchases under the new $500 million program may be made from time to time on the open market, pursuant to Rule 10b5-1 trading plans, or other legally permissible means. The share repurchase program has no time limit, does not obligate Dynatrace to acquire a specified number of shares, and may be suspended, modified, or terminated at any time, without prior notice. The number of shares to be repurchased will depend on market conditions and other factors. Repurchases under the program are expected to be funded from a combination of existing cash balances and future cash flow.

06:08 EDT Webuy launches travel business in Indonesia - Webuy Global announced the launch of its travel business in Indonesia, as it expands its presence in the growing Southeast Asian tourism market.

06:04 EDT Dorian LPG sees Q4 TCE revenue $140M-$142M - Q4 revenue consensus $152.73M.

06:02 EDT Unity announces resignation of chief product and technology officer, Create - In a regulatory filing, Unity Software announced that Marc Whitten will resign as the company's Chief Product and Technology Officer, Create, effective as of June 1. Whitten will assist with the transition of his responsibilities and has agreed to continue serving as an employee until he departs from the company, effective December 31. In connection with his resignation and transition, the company and Whitten entered into a resignation and transition agreement, pursuant to which, from the Transition Date until the Resignation Date Whitten will serve as a Strategic Advisor.

05:21 EDT Blue Hat Interactive appoints AI digital person 'Aileen' as CIO - Driven by artificial intelligence technology, Blue Hat Interactive announced that an independently developed AI digital person, " Aileen," will serve as the company's chief information officer, or CIO. The development of this AI digital person is based on the company's long-term technical buildup in the gaming field and in-depth application of market-leading third-party AI technology, marking an important step for BHAT in the field of AI application services.